News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Says MabThera Gets Positive Phase III Data
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 26 (Reuters) - Lymph cancer treatment MabThera has been shown to work as a maintenance therapy in patients with relapsed indolent non-Hodgkin's lymphoma, according to initial details from a Phase III study released by Roche on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Roche
MORE ON THIS TOPIC
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
January 14, 2026
·
2 min read
·
Heather McKenzie
Policy
Acadia CEO Bands With Peers To Lobby Against MFN Drug Pricing for Small Biotech
January 13, 2026
·
3 min read
·
Annalee Armstrong
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
·
3 min read
·
Nick Paul Taylor
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
January 13, 2026
·
3 min read
·
Tristan Manalac
